Morepen Laboratories Share News - Latest Updates, Live News & More

Latest news about Morepen Laboratories

Morepen Laboratories Expands into Medical Devices with New Subsidiary Aug 13, 2025

Morepen Laboratories Limited has incorporated a new step-down subsidiary, Sigmacheck Health Private Limited, to enter the medical devices industry. The subsidiary, approved on August 13, 2025, has an authorized and paid-up capital of ₹1,00,000. Morepen Laboratories holds a 60% indirect stake through its wholly-owned subsidiary, Morepen Medipath Limited. This strategic move aims to diversify Morepen's portfolio and capitalize on the growing healthcare equipment market.

Morepen Laboratories Reports Q1 Results, Sets Dividend Record Date, and Approves Leadership Changes Aug 06, 2025

Morepen Laboratories Reshapes Business Portfolio: Sells Stake in Dr. Morepen, Indirectly Acquires Groom Town Aug 01, 2025

Morepen Laboratories Expands into Medical Devices with New Subsidiary SIGMACHECK HEALTH Jul 25, 2025

Morepen Laboratories Expands Global Footprint with New Dubai Subsidiary Jul 22, 2025

More news about Morepen Laboratories

30Jun 25

Morepen Laboratories Reduces Stake in Morepen Medipath to 60%

Morepen Laboratories has decreased its ownership stake in its subsidiary, Morepen Medipath Ltd, to 60% following a new share issuance by the subsidiary. This move has resulted in a dilution of Morepen Laboratories' ownership in Morepen Medipath. The share issuance could indicate a strategy to raise additional capital for the subsidiary, potentially for expansion plans or strengthening its financial position.

12May 25

Morepen Laboratories Amends Business Transfer Agreement with Morepen Medipath

Morepen Laboratories Ltd. has executed an addendum to its existing Business Transfer Agreement with Morepen Medipath. This modification could potentially affect the scope of business transfer, financial terms, or operational arrangements between the two entities. The amendment suggests that Morepen Laboratories is adapting its business strategy to current market conditions or corporate objectives. While specific details of the addendum are not disclosed, this change may have implications for shareholders, employees, and business partners.

12May 25

Morepen Laboratories Reports Mixed Q4 Results: Revenue Up, Profits Down, Plans Dubai Subsidiary

Morepen Laboratories announced Q4 financial results with total income rising to ₹470.00 crore, up 11.11% year-over-year. However, net profit declined 31.03% to ₹20.00 crore, and EBITDA fell to ₹42.30 crore. Full-year FY25 net profit increased to ₹118.00 crore. The company declared a dividend of ₹0.20 per share and plans to establish a new subsidiary in Dubai.

29Apr 25

Morepen Laboratories Expands Global Footprint with Dubai Subsidiary, Management Reshuffle, and CDSCO Approval for Resmetirom Studies

Morepen Laboratories Limited is establishing a wholly-owned subsidiary in Dubai's Free Zone to enhance international operations. The company has promoted Kushal Suri to President – International Growth. Additionally, Morepen received CDSCO approval for bioequivalence studies of Resmetirom, a potential NASH treatment, positioning it among the first Indian companies ready for the drug's global launch.

28Apr 25

Morepen Laboratories Expands Global Footprint with New Dubai Subsidiary

Morepen Laboratories Limited plans to set up a wholly-owned subsidiary in Dubai, UAE, named Morepen Labs FZCO. The company will invest AED 50,000 (approx. INR 11.25 lakhs) as initial capital. The new entity will focus on sales and marketing of Morepen's products internationally. Additionally, Mr. Kushal Suri has been appointed as President of International Growth, effective April 28, 2025.

24Apr 25

Morepen Labs Launches New Products, Aims for Rs 1,000 Crore in Formulation Business

Morepen Laboratories introduced four new prescription products in April 2025, aiming to expand its formulation business from Rs 325 crore to Rs 1,000 crore over the next five years. This launch is part of the company's R&D-driven growth strategy in the pharmaceutical sector.

11Apr 25

Morepen Laboratories Unveils Ambitious Plan to Expand Salesforce by Over 1,000 Professionals

Morepen Laboratories plans to add over 1,000 professionals to its salesforce in the next three years, with 200 joining in FY26. This expansion aims to strengthen its domestic market presence and deepen connections with healthcare stakeholders. The company targets growing its ₹325 crore formulations business to ₹1,000 crore within five years. This strategy aligns with India's healthcare vision and the projected growth of the Indian pharmaceutical market to $130 billion by 2030.

01Apr 25

Morepen Laboratories Expands Global Reach: Secures Loratadine Approval for China Export

Morepen Laboratories has received approval from China's National Medical Products Administration to export Loratadine, an antihistamine API, to the Chinese market. The company commands over 80% market share in the US generics market for Loratadine and exports to 82 countries. Morepen has a manufacturing capacity of 144 metric tons of API annually and USFDA-approved facilities. Recently, its US subsidiary acquired shares in ICB International, Inc., and Dr. Morepen Limited transitioned from a wholly-owned subsidiary to a subsidiary with an 80% stake.

19Mar 25

Morepen Laboratories Finalizes Business Transfer Agreement with Subsidiary Morepen Medtech

Morepen Laboratories Ltd. has executed a Business Transfer Agreement with its subsidiary, Morepen Medtech Limited, to transfer its Medical Devices Business as a 'slump sale'. The agreement, signed on March 18, 2025, involves the hiving-off of the business to the subsidiary, in which Morepen Laboratories holds 80% equity. The transaction, approved by shareholders and compliant with regulatory requirements, is conducted on an arm's length basis. The final consideration is subject to adjustments based on closing terms.

18Mar 25

Morepen Laboratories Finalizes Business Transfer Agreement with Subsidiary Morepen Medtech

Morepen Laboratories has executed a Business Transfer Agreement to transfer its Medical Devices Business to its subsidiary, Morepen Medtech Limited, as a 'slump sale'. The subsidiary is 80% owned by Morepen Laboratories, with the remaining 20% held by the promoter group and related entities. The transfer valuation will be based on Rule 11UAE of Income Tax Rules, 1962, with the final consideration subject to adjustments. This strategic move aims to streamline operations and enhance efficiency in both pharmaceutical and medical device sectors.

18Mar 25

Morepen Laboratories Unveils Empamore: A Game-Changer in Diabetes, Heart Failure, and Kidney Disease Treatment

Morepen Laboratories has introduced Empamore, a new treatment for Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease. Based on Empagliflozin, Empamore is priced 90% lower than existing brands, aiming to provide affordable access to quality treatment in India. The drug is manufactured in USFDA-approved facilities and comes in multiple formulations. With India's growing diabetes market and Morepen's global presence in 82 countries, this launch could significantly impact both patient care and the company's market position.